These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10638484)

  • 1. RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.
    Beaupre DM; Kurzrock R
    Invest New Drugs; 1999; 17(2):137-43. PubMed ID: 10638484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of farnesyltransferase inhibitors in hematologic malignancies.
    Santos ES; Rosenblatt JD; Goodman M
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate and Ras methylation: a new trick for an old drug?
    Philips MR
    Sci STKE; 2004 Mar; 2004(225):pe13. PubMed ID: 15039490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?
    Shinohara N; Koyanagi T
    Urol Res; 2002 Oct; 30(5):273-81. PubMed ID: 12389114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Ras pathway in pediatric hematologic malignancies.
    Pikman Y; Stieglitz E
    Curr Opin Pediatr; 2021 Feb; 33(1):49-58. PubMed ID: 33394740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugging RAS: Know the enemy.
    Papke B; Der CJ
    Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
    Dhawan NS; Scopton AP; Dar AC
    Nature; 2016 Sep; 537(7618):112-116. PubMed ID: 27556948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Past, Present, and Future of Targeting Ras for Cancer Therapies.
    Tan Z; Zhang S
    Mini Rev Med Chem; 2016; 16(5):345-57. PubMed ID: 26423695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies to target RAS-mutant cancers.
    Ryan MB; Corcoran RB
    Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking Ras inhibition as an antitumor strategy.
    Marín-Ramos NI; Ortega-Gutiérrez S; López-Rodríguez ML
    Semin Cancer Biol; 2019 Feb; 54():91-100. PubMed ID: 29409706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?
    Cierpicki T; Grembecka J
    Immunol Rev; 2015 Jan; 263(1):279-301. PubMed ID: 25510283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeting the RAS signalling pathway in cancer].
    Mansi L; Viel E; Curtit E; Medioni J; Le Tourneau C
    Bull Cancer; 2011 Oct; 98(9):1019-28. PubMed ID: 21715253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.
    Baines AT; Lim KH; Shields JM; Lambert JM; Counter CM; Der CJ; Cox AD
    Methods Enzymol; 2006; 407():556-74. PubMed ID: 16757353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic RAS: From Its Activation to Its Direct Targeting.
    Zaravinos A
    Crit Rev Oncog; 2017; 22(3-4):283-301. PubMed ID: 29604905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
    Huynh MV; Campbell SL
    Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Targeting KRAS pathway in NSCLC therapy].
    Le Moulec S; Loriot Y; Soria JC
    Bull Cancer; 2009 Dec; 96 Suppl():S69-74. PubMed ID: 20034872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction.
    Khazak V; Kato-Stankiewicz J; Tamanoi F; Golemis EA
    Methods Enzymol; 2006; 407():612-29. PubMed ID: 16757356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras in digestive oncology: from molecular biology to clinical implications.
    Charette N; Vandeputte C; Stärkel P
    Curr Opin Oncol; 2014 Jul; 26(4):454-61. PubMed ID: 24849046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.